logo
[breadcrumb_custom]

Tag: CBAY Shares

ZM Stock
Finance

CBAY’s Stock Market Puzzle: Piecing Together 2023’s Performance

A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price increase of 37.53%. However, over the past six months, we’ve seen a weaker performance of 121.89%. The price of CBAY fallen by 0.92% over the last 30 days. And in the last five days, it has surged by 0.05%. Cymabay Therapeutics Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $32.49 on 03/21/24, with the lowest value being $7.26

Industry

Cymabay Therapeutics Inc (CBAY) Stock: Navigating Drops and Gains

A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Cymabay Therapeutics Inc’s current trading price is 0.28% away from its 52-week high, while its distance from the 52-week low is 346.78%. The stock’s price range for this time frame has been between $7.26 and $32.35. The trading volume of the company’s shares in the Healthcare reached around 6.11 million for the day, which was evidently higher than the average daily volume of 3.68 million over the last three months. The market performance of Cymabay Therapeutics Inc has been

HCCC Stock
News

Cymabay Therapeutics Inc (CBAY) Stock: 52-Week Performance Insights and Trading Volume

The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Cymabay Therapeutics Inc’s current trading price is -0.11% away from its 52-week high, while its distance from the 52-week low is 345.06%. The stock’s price range for this period has been between $7.26 and $32.35 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 0.98 million for the day, a number notably lower than the average daily volume of 3.68 million over the last three months. In terms of market performance, Cymabay Therapeutics